Former OpenAI science lead launches Warp Sciences to automate drug discovery labs

Startup raises $215 million to train robots for wet-lab work, aiming to reshore biotech manufacturing from China

By LineZotpaper

Published22 October 2026

Read Time1 min

Sources2 outlets

Kevin Weil, formerly OpenAI's science lead, has launched Warp Sciences, an AI startup that trains robots to automate wet-lab tasks for drug discovery. The company has raised $215 million at an $865 million valuation, with Lightspeed leading the round alongside IVP, Premji Invest, and Lux Capital.

Kevin Weil, previously OpenAI's science lead, has announced the launch of Warp Sciences, a startup that uses artificial intelligence and robotics to automate laboratory work for drug development. The company aims to accelerate the process of synthesizing and testing compounds identified by researchers by training robots to perform wet-lab tasks.

Weil announced the startup and its funding on X. The $215 million round was led by Lightspeed, with participation from IVP, Premji Invest, and Lux Capital, giving the company an $865 million valuation.

For years, biotech companies have outsourced the labor-intensive work of synthesizing thousands of molecular variations to contractors in China, such as WuXi AppTec. Warp Sciences plans to reshore that work, insulating the drug development process from geopolitical supply-chain risks.

The startup's human chemists, wearing cameras and sensor gloves, will train robots to perform various lab tasks. By automating wet-lab work, Warp Sciences hopes to enable around-the-clock drug discovery operations.

Analysis

Why This Matters

Warp Sciences targets the bottleneck of drug discovery: the slow, manual synthesis and testing of compounds. Automating this could cut development timelines significantly.
The reshoring of biotech lab work addresses a geopolitical vulnerability: the US and other countries rely heavily on Chinese contract research organisations.
The large funding round signals strong investor confidence in AI-driven robotics for life sciences, a trend that could reshape the pharmaceutical supply chain.

Background

Wet-lab work in drug discovery involves synthesising and testing thousands of molecular variants, a tedious process that has traditionally been outsourced to low-cost countries, particularly China. Companies like WuXi AppTec have become critical partners for biotech firms. However, rising geopolitical tensions and supply-chain disruptions have spurred interest in automation and reshoring. Kevin Weil previously led scientific research at OpenAI, giving him a background at the intersection of AI and science.

Key Perspectives

Kevin Weil and Warp Sciences: The startup aims to combine AI with robotics to automate tedious lab tasks, making drug discovery faster and more resilient to geopolitical risks. The investment round shows backers agree. Investors (Lightspeed, IVP, Premji Invest, Lux Capital): They are betting that AI-trained robots can replace expensive and slow human labour in wet labs, potentially revolutionising pharmaceutical R&D. Biotech industry incumbents: Existing contractors in China may face disruption if Warp Sciences successfully reshores synthesis work. However, scaling such automation is unproven, and regulatory hurdles for automated labs remain.

What to Watch

Whether Warp Sciences can demonstrate a meaningful reduction in drug discovery timelines with its robot-trained system.
The response from Chinese contract research organisations and any shifts in global biotech manufacturing.
Potential regulatory challenges for automated labs handling hazardous materials or controlled substances.

Sources

Former OpenAI science lead launches Warp Science to automate wet labs with robots · TechCrunch
Former OpenAI science lead launches Warp Science to automate wet labs with robots · Startups | TechCrunch

Checked

10 claims in this story checked against 1 source: 7 supported.

Show each claim

SupportedFormer OpenAI science lead Kevin Weil launched Warp Sciences to automate drug-discovery labs.TechCrunch: “Former OpenAI science lead Kevin Weil has launched Warp Sciences, a new AI startup focused on automating lab work for drug discovery.”
Partly supportedWarp Sciences raised $215 million at an $865 million valuation.TechCrunch: “The company, which trains robots to make and test promising compounds identified by researchers, has raised $215 million at an $865 million valuation, according to Weil”
SupportedThe startup’s funding round was led by Lightspeed, with participation from IVP, Premji Invest and Lux Capital.TechCrunch: “The round was led by Lightspeed, with participation from IVP, Premji Invest, and Lux Capital.”
SupportedWarp Sciences trains robots to perform wet-lab work for drug discovery.TechCrunch: “The company, which trains robots to make and test promising compounds identified by researchers”
Partly supportedWarp Sciences is aiming to reshore biotech manufacturing from China.TechCrunch: “For years, biotech companies have outsourced the most labor-intensive work of synthesizing thousands of variations of molecules to contractors in China, such as WuXi AppTec. With Warp Sciences, Weil hopes to reshore that work”
SupportedWeil announced Warp Sciences and its funding on X.TechCrunch: “according to Weil, who announced the startup and funding on X.”
SupportedWarp Sciences aims to accelerate synthesizing and testing compounds identified by researchers.TechCrunch: “The company, which trains robots to make and test promising compounds identified by researchers”
Partly supportedWarp Sciences plans to reshore the work and insulate the drug-development process from geopolitical supply-chain risks.TechCrunch: “With Warp Sciences, Weil hopes to reshore that work and insulate the entire drug development process from geopolitical supply-chain risks.”
SupportedThe startup’s human chemists will wear cameras and sensor gloves to train robots to perform lab tasks.TechCrunch: “Wearing cameras and sensor gloves, the startup’s human chemists will train robots to perform various lab tasks.”
SupportedWarp Sciences hopes to enable around-the-clock drug-discovery operations.TechCrunch: “By automating wet-lab work, Warp Sciences aims to accelerate drug discovery using robots that can operate around the clock.”